HRP20231092T1 - Inhibitori arginaze i postupci njihove primjene - Google Patents

Inhibitori arginaze i postupci njihove primjene Download PDF

Info

Publication number
HRP20231092T1
HRP20231092T1 HRP20231092TT HRP20231092T HRP20231092T1 HR P20231092 T1 HRP20231092 T1 HR P20231092T1 HR P20231092T T HRP20231092T T HR P20231092TT HR P20231092 T HRP20231092 T HR P20231092T HR P20231092 T1 HRP20231092 T1 HR P20231092T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
formula
image
Prior art date
Application number
HRP20231092TT
Other languages
English (en)
Croatian (hr)
Inventor
Scott Nathan MLYNARSKI
Tyler GREBE
Sameer KAWATKAR
Maurice Raymond Verschoyle Finlay
Iain Simpson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20231092T1 publication Critical patent/HRP20231092T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20231092TT 2019-02-08 2020-02-07 Inhibitori arginaze i postupci njihove primjene HRP20231092T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08
PCT/IB2020/050982 WO2020161675A1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof
EP20709706.4A EP3921033B1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20231092T1 true HRP20231092T1 (hr) 2023-12-22

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231092TT HRP20231092T1 (hr) 2019-02-08 2020-02-07 Inhibitori arginaze i postupci njihove primjene

Country Status (32)

Country Link
US (2) US12435097B2 (cg-RX-API-DMAC7.html)
EP (1) EP3921033B1 (cg-RX-API-DMAC7.html)
JP (1) JP7526734B2 (cg-RX-API-DMAC7.html)
KR (1) KR102759971B1 (cg-RX-API-DMAC7.html)
CN (1) CN113395996B (cg-RX-API-DMAC7.html)
AU (1) AU2020218651B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015581A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002056A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021011039A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210463A (cg-RX-API-DMAC7.html)
DK (1) DK3921033T3 (cg-RX-API-DMAC7.html)
DO (2) DOP2021000166A (cg-RX-API-DMAC7.html)
EA (1) EA202192114A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960034T3 (cg-RX-API-DMAC7.html)
FI (1) FI3921033T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231092T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062968T2 (cg-RX-API-DMAC7.html)
IL (1) IL285108B2 (cg-RX-API-DMAC7.html)
LT (1) LT3921033T (cg-RX-API-DMAC7.html)
MA (1) MA56324B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021009499A (cg-RX-API-DMAC7.html)
MY (1) MY206577A (cg-RX-API-DMAC7.html)
PE (1) PE20220280A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551902A1 (cg-RX-API-DMAC7.html)
PL (1) PL3921033T3 (cg-RX-API-DMAC7.html)
PT (1) PT3921033T (cg-RX-API-DMAC7.html)
RS (1) RS64781B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108503PA (cg-RX-API-DMAC7.html)
SI (1) SI3921033T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300337T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020161675A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202105833B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
SE0300907D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
WO2010085797A2 (en) 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Arginase inhibitors and methods of use
EP2560978B1 (en) * 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3034509B1 (en) * 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
CA2852685C (en) 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
PL410665A1 (pl) * 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2016281620B2 (en) * 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2017175185A1 (en) * 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2018119440A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108794517B (zh) * 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US12215116B2 (en) * 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019205979A1 (zh) * 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
MA53427B1 (fr) 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
DK3921033T3 (da) 2023-10-16
AU2020218651B2 (en) 2023-01-12
MY206577A (en) 2024-12-24
JP2022521474A (ja) 2022-04-08
KR102759971B1 (ko) 2025-01-23
DOP2021000166A (es) 2021-09-30
IL285108B1 (en) 2024-06-01
IL285108A (en) 2021-09-30
MX2021009499A (es) 2021-09-08
KR20210126044A (ko) 2021-10-19
PL3921033T3 (pl) 2024-01-15
BR112021015581A2 (pt) 2021-10-05
HUE062968T2 (hu) 2023-12-28
CL2021002056A1 (es) 2022-03-04
ZA202105833B (en) 2025-03-26
ES2960034T3 (es) 2024-02-29
PE20220280A1 (es) 2022-02-25
CR20210463A (es) 2021-10-15
IL285108B2 (en) 2024-10-01
WO2020161675A1 (en) 2020-08-13
CN113395996A (zh) 2021-09-14
US20220106335A1 (en) 2022-04-07
RS64781B1 (sr) 2023-11-30
EA202192114A1 (ru) 2021-12-01
SG11202108503PA (en) 2021-09-29
EP3921033B1 (en) 2023-07-26
JP7526734B2 (ja) 2024-08-01
US12435097B2 (en) 2025-10-07
CA3127755A1 (en) 2020-08-13
PH12021551902A1 (en) 2022-08-01
SMT202300337T1 (it) 2023-11-13
FI3921033T3 (fi) 2023-09-15
CN113395996B (zh) 2024-05-28
EP3921033A1 (en) 2021-12-15
SI3921033T1 (sl) 2023-11-30
LT3921033T (lt) 2023-09-25
CO2021011039A2 (es) 2021-09-09
AU2020218651A1 (en) 2021-09-30
US20250282800A1 (en) 2025-09-11
MA56324B1 (fr) 2023-10-31
DOP2024000181A (es) 2024-10-15
PT3921033T (pt) 2023-10-11

Similar Documents

Publication Publication Date Title
IL276711B2 (en) Arginase inhibitors and methods of use thereof
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
CY1122863T1 (el) Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα
HRP20241197T1 (hr) Makrociklični spojevi i primjene istih
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20250282T1 (hr) Fuzijski tri-ciklički spoj kao dvostruki inhibitor pde3/pde4
HRP20200561T1 (hr) Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
HRP20170955T1 (hr) Derivati kinolin-8-sulfonamida s antikancerogenim djelovanjem
JP2016506962A5 (cg-RX-API-DMAC7.html)
HRP20161103T1 (hr) Kemijski spojevi
RU2009115784A (ru) Производные пиразоло[1,5-а]пиримидина и их применение в медицине
AR041009A1 (es) Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih
HRP20180063T1 (hr) Lipidirani derivati imidazokinolina
CA2624621A1 (en) Pyrazine derivatives
GEAP202215588A (en) N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
MA33501B1 (fr) Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
DOP2024000181A (es) Inhibidores de arginasa y métodos de uso de estos
RU2013136895A (ru) Новое бициклическое соединение или его соль
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
PL420626A1 (pl) Nowe pochodne karbaminianów oraz ich zastosowanie
JP2022501315A5 (cg-RX-API-DMAC7.html)
CY1112596T1 (el) Νεες ενωσεις και χρηση αυτων
TH2001004359A (th) ตัวยับยั้งอาร์จิเนสและวิธีการใช้สิ่งดังกล่าว
DK2117552T3 (da) Anvendelse af kondenserede pyrimidinderivater til behandling af autoimmum- og inflammationssygdomme